Neurocrine Biosciences Reports Q2 2026 Earnings with Strong Revenue Growth
Neurocrine Biosciences (NBIX) reported second-quarter revenue of $950 million for the period ending July 30, 2026. The results were driven by full contributions from INGREZZA and CRENESSITY, along with partial performance from its newly acquired VYKAT XR franchise following a May acquisition. INGREZZA net sales reached $716 million in Q2, up 15% year-over-year due to strong new-patient additions. The company raised INGREZZA’s annual guidance to between $2.825 billion and $2.875 billion from a prior range of $2.7 billion to $2.8 billion. CRENESSITY net sales grew 20% sequentially, reaching $184 million with strong performance in both adult and pediatric segments. The company acquired Soleno Therapeutics for $2.9 billion using cash on hand, expanding its rare disease portfolio while maintaining a debt-free balance sheet. Neurocrine also highlighted key clinical milestones expected by the end of 2027.
Topics: acquisition drug_sales non-gaap_eps revenue